Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5880MR)

This product GTTS-WQ5880MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5880MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1292MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ11046MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ7213MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ10589MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ15764MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ4963MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ13140MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ7519MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-1102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW